Celiac Disease in Childhood-Adulthood Transition
Launched by TAMPERE UNIVERSITY HOSPITAL · Oct 7, 2021
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Celiac disease is one of the most common chronic gastrointestinal diseases affecting 1-3% of population worldwide. It is treated with life-long and strict gluten-free diet. When dietary treatment is successful, prognosis of pediatric patients seems to be excellent whereas ongoing predisposition to gluten may increase the risk even to permanent complications. However, gluten-free diet may cause burden and restrictions in everyday life impairing quality of life. Regular follow-up is recommended to support the treatment and to detect early possible comorbidities and complications, but, in prac...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • verified celiac disease diagnosis in childhood (\<16 years of age)
- • age 13-19 years at recruitment
- • Finnish-speaking
- Exclusion Criteria:
- • disease or condition preventing the completing of the study questionnaire
- • Inclusion criteria for controls
- • no celiac disease diagnosis
- • age 13-19 years at recruitment
- • Finnish-speaking
About Tampere University Hospital
Tampere University Hospital (TAYS) is a leading academic medical center in Finland, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, TAYS integrates cutting-edge medical practices with rigorous scientific investigation, focusing on improving patient outcomes and enhancing treatment modalities across various specialties. The hospital collaborates with a network of researchers, healthcare professionals, and academic institutions to foster a multidisciplinary approach to medical research, ensuring that findings are translated into real-world applications for the benefit of patients and the broader healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lappeenranta, , Finland
Kuopio, , Finland
Seinäjoki, , Finland
Turku, , Finland
Tampere, , Finland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials